secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2025-09-05T23:59:59+00:00
Accession:  0001193125-25-197250
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports new mouse-model data showing complete tumor regression and immune memory for ACR-368 and ACR-2316 combos
--------------------------------------------------------------------------------

- Syngeneic mouse model: sustained complete tumor regression and immune memory after multiple implant rounds over ~1 year.
- Data supports rationale for front-line combination of ACR-368 and ACR-2316 with anti-PD(L)1 agents.
- Pipeline update adds all-comer ACR-368 + ULDG ARM 3 of ongoing ACR-368-201 trial.
- AP3 platform update highlights capability to generate actionable pathway insights for novel drug design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312525197250/0001193125-25-197250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312525197250/acrv-20250905.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-197250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer